TATYY vs. AZN
TATYY (Tate & Lyle PLC ADR) and AZN (AstraZeneca PLC) are both stocks. TATYY operates in Packaged Foods (Consumer Defensive), while AZN operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, TATYY returned 3.85%/yr vs 15.87%/yr for AZN. At a 0.11 correlation, their price movements are largely independent.
Performance
TATYY vs. AZN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TATYY achieves a 47.41% return, which is significantly higher than AZN's 0.51% return. Over the past 10 years, TATYY has underperformed AZN with an annualized return of 3.85%, while AZN has yielded a comparatively higher 15.87% annualized return.
TATYY
- 1D
- -3.58%
- 1M
- 8.83%
- YTD
- 47.41%
- 6M
- 47.04%
- 1Y
- 5.87%
- 3Y*
- -4.18%
- 5Y*
- -1.23%
- 10Y*
- 3.85%
AZN
- 1D
- 2.60%
- 1M
- -3.21%
- YTD
- 0.51%
- 6M
- 0.29%
- 1Y
- 31.72%
- 3Y*
- 10.40%
- 5Y*
- 11.70%
- 10Y*
- 15.87%
TATYY vs. AZN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
TATYY Tate & Lyle PLC ADR | 47.41% | -35.21% | -0.61% | -0.36% | 18.05% | -0.65% | -1.93% | 19.27% | -4.33% | 9.74% |
AZN AstraZeneca PLC | 0.51% | 43.30% | -0.62% | 1.44% | 19.14% | 19.66% | 3.12% | 35.68% | 13.86% | 33.10% |
Correlation
The correlation between TATYY and AZN is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.12 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.11 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since Jan 4, 2016 | 0.11 |
Fundamentals
TATYY:
$3.26B
AZN:
$282.57B
TATYY:
£2.15
AZN:
$6.66
TATYY:
10.26
AZN:
27.19
TATYY:
0.70
AZN:
4.67
TATYY:
1.55
AZN:
5.97
TATYY:
£3.54B
AZN:
$60.44B
TATYY:
£722.00M
AZN:
$49.37B
TATYY:
£597.20M
AZN:
$20.47B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TATYY vs. AZN — Risk / Return Rank
TATYY
AZN
TATYY vs. AZN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Tate & Lyle PLC ADR (TATYY) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TATYY | AZN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.15 | ||
| Sortino ratioReturn per unit of downside risk | -1.31 | ||
| Omega ratioGain probability vs. loss probability | 1.10 | 1.23 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 0.15 | 1.99 | -1.84 |
| Martin ratioReturn relative to average drawdown | 0.23 | 5.21 | -4.99 |
Loading charts...
Drawdowns
TATYY vs. AZN - Drawdown Comparison
The maximum TATYY drawdown since its inception was -57.06%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for TATYY and AZN.
Loading charts...
Drawdown Indicators
| TATYY | AZN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -57.06% | -48.94% | -8.12% |
Max Drawdown (1Y)Largest decline over 1 year | -40.33% | -16.08% | -24.25% |
Max Drawdown (3Y)Largest decline over 3 years | -57.06% | -27.87% | -29.19% |
Max Drawdown (5Y)Largest decline over 5 years | -57.06% | -27.87% | -29.19% |
Max Drawdown (10Y)Largest decline over 10 years | -57.06% | -27.87% | -29.19% |
Current DrawdownCurrent decline from peak | -27.40% | -13.16% | -14.24% |
Average DrawdownAverage peak-to-trough decline | -15.61% | -11.37% | -4.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.05% | 6.12% | +19.93% |
Volatility
TATYY vs. AZN - Volatility Comparison
Tate & Lyle PLC ADR (TATYY) has a higher volatility of 13.66% compared to AstraZeneca PLC (AZN) at 7.99%. This indicates that TATYY's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TATYY | AZN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.66% | 7.99% | +5.67% |
Volatility (6M)Calculated over the trailing 6-month period | 44.51% | 17.73% | +26.78% |
Volatility (1Y)Calculated over the trailing 1-year period | 57.30% | 25.60% | +31.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.16% | 24.09% | +14.07% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.04% | 24.88% | +9.16% |
Dividends
TATYY vs. AZN - Dividend Comparison
TATYY's dividend yield for the trailing twelve months is around 3.62%, more than AZN's 2.94% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 2.94% | 1.70% | 2.27% | 2.15% | 2.12% | 2.35% | 2.80% | 2.81% | 3.69% | 3.95% | 5.01% | 4.06% |
TATYY Tate & Lyle PLC ADR | 3.62% | 5.27% | 3.03% | 2.90% | 19.44% | 4.72% | 3.74% | 3.67% | 4.18% | 3.64% | 3.81% | 0.00% |
Financials
TATYY vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Tate & Lyle PLC ADR and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TATYY vs. AZN - Profitability Comparison
TATYY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Tate & Lyle PLC ADR reported a gross profit of 0.00 and revenue of 996.75M. Therefore, the gross margin over that period was 0.0%.
AZN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.
TATYY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Tate & Lyle PLC ADR reported an operating income of 83.23M and revenue of 996.75M, resulting in an operating margin of 8.4%.
AZN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.
TATYY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Tate & Lyle PLC ADR reported a net income of 41.62M and revenue of 996.75M, resulting in a net margin of 4.2%.
AZN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.
Frequently Asked Questions
TATYY and AZN have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TATYY has higher volatility (13.66%) compared to AZN (7.99%). In terms of maximum drawdown, TATYY dropped -57.06% vs AZN's -48.94%.
AZN currently has the higher Sharpe Ratio (1.25 vs 0.10), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TATYY and AZN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer